Cargando…
The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial
Prior research has shown that in experimental diabetes mellitus, green tea reduces albuminuria by decreasing podocyte apoptosis through activation of the WNT pathway. We investigated the effect of green tea polyphenols (GTP) on residual albuminuria of diabetic subjects with nephropathy. We conducted...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913255/ https://www.ncbi.nlm.nih.gov/pubmed/27320846 http://dx.doi.org/10.1038/srep28282 |
_version_ | 1782438389225619456 |
---|---|
author | Borges, Cynthia M. Papadimitriou, Alexandros Duarte, Diego A. Lopes de Faria, Jacqueline M. Lopes de Faria, José B. |
author_facet | Borges, Cynthia M. Papadimitriou, Alexandros Duarte, Diego A. Lopes de Faria, Jacqueline M. Lopes de Faria, José B. |
author_sort | Borges, Cynthia M. |
collection | PubMed |
description | Prior research has shown that in experimental diabetes mellitus, green tea reduces albuminuria by decreasing podocyte apoptosis through activation of the WNT pathway. We investigated the effect of green tea polyphenols (GTP) on residual albuminuria of diabetic subjects with nephropathy. We conducted a randomised, double-blind study in 42 diabetic subjects with a urinary albumin-creatinine ratio (UACR) >30 mg/g, despite administration of the maximum recommended dose of renin-angiotensin (RAS) inhibition. Patients were randomly assigned to two equal groups to receive either GTP (containing 800 mg of epigallocatechin gallate, 17 with type 2 diabetes and 4 with type 1 diabetes) or placebo (21 with type 2 diabetes) for 12 weeks. Treatment with GTP reduced UACR by 41%, while the placebo group saw a 2% increase in UACR (p = 0.019). Podocyte apoptosis (p = 0.001) and in vitro albumin permeability (p < 0.001) were higher in immortalized human podocytes exposed to plasma from diabetic subjects compared to podocytes treated with plasma from normal individuals. In conclusion, GTP administration reduces albuminuria in diabetic patients receiving the maximum recommended dose of RAS. Reduction in podocyte apoptosis by activation of the WNT pathway may have contributed to this effect. |
format | Online Article Text |
id | pubmed-4913255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49132552016-06-21 The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial Borges, Cynthia M. Papadimitriou, Alexandros Duarte, Diego A. Lopes de Faria, Jacqueline M. Lopes de Faria, José B. Sci Rep Article Prior research has shown that in experimental diabetes mellitus, green tea reduces albuminuria by decreasing podocyte apoptosis through activation of the WNT pathway. We investigated the effect of green tea polyphenols (GTP) on residual albuminuria of diabetic subjects with nephropathy. We conducted a randomised, double-blind study in 42 diabetic subjects with a urinary albumin-creatinine ratio (UACR) >30 mg/g, despite administration of the maximum recommended dose of renin-angiotensin (RAS) inhibition. Patients were randomly assigned to two equal groups to receive either GTP (containing 800 mg of epigallocatechin gallate, 17 with type 2 diabetes and 4 with type 1 diabetes) or placebo (21 with type 2 diabetes) for 12 weeks. Treatment with GTP reduced UACR by 41%, while the placebo group saw a 2% increase in UACR (p = 0.019). Podocyte apoptosis (p = 0.001) and in vitro albumin permeability (p < 0.001) were higher in immortalized human podocytes exposed to plasma from diabetic subjects compared to podocytes treated with plasma from normal individuals. In conclusion, GTP administration reduces albuminuria in diabetic patients receiving the maximum recommended dose of RAS. Reduction in podocyte apoptosis by activation of the WNT pathway may have contributed to this effect. Nature Publishing Group 2016-06-20 /pmc/articles/PMC4913255/ /pubmed/27320846 http://dx.doi.org/10.1038/srep28282 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Borges, Cynthia M. Papadimitriou, Alexandros Duarte, Diego A. Lopes de Faria, Jacqueline M. Lopes de Faria, José B. The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial |
title | The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial |
title_full | The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial |
title_fullStr | The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial |
title_full_unstemmed | The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial |
title_short | The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial |
title_sort | use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: a double-blind randomised clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913255/ https://www.ncbi.nlm.nih.gov/pubmed/27320846 http://dx.doi.org/10.1038/srep28282 |
work_keys_str_mv | AT borgescynthiam theuseofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT papadimitrioualexandros theuseofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT duartediegoa theuseofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT lopesdefariajacquelinem theuseofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT lopesdefariajoseb theuseofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT borgescynthiam useofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT papadimitrioualexandros useofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT duartediegoa useofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT lopesdefariajacquelinem useofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial AT lopesdefariajoseb useofgreenteapolyphenolsfortreatingresidualalbuminuriaindiabeticnephropathyadoubleblindrandomisedclinicaltrial |